GlassScriptPhysician profile
Thomas H Patterson
NPI 1568460970
$2,847.94
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $76.98 · 2021: $1,818 · 2022: $55.31 · 2023: $332 · 2024: $127 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,639.86 | 2021-2025 | Lynparza, Farxiga |
| Astellas Pharma US INC | $456.84 | 2019-2024 | Xtandi, Veozah |
| Olympus America INC. | $106.24 | 2019-2023 | Soltive, Olympus |
| Merck Sharp & Dohme LLC | $80.60 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $59.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.56 | 2019 | |
| Pfizer INC. | $53.67 | 2019-2020 | |
| Abbvie INC. | $48.98 | 2019-2025 | |
| Abbott Laboratories | $46.18 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $35.59 | 2023-2024 | Prolia, Evenity |
| Boston Scientific Corporation | $32.15 | 2025 | Axonics |
| Otsuka America Pharmaceutical, INC. | $24.48 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Blue Earth Diagnostics | $23.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.13 | 2024 | Xarelto |
| Zimmer Biomet Holdings, INC. | $19.82 | 2025 | Persona |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.70 | 2025 | Inceptiv |
| Myovant Sciences INC. | $18.22 | 2021 | |
| Novo Nordisk INC | $17.89 | 2023 | Rybelsus, Ozempic |
| Myriad Genetic Laboratories, INC. | $17.51 | 2023 | Prolaris |
| Janssen Biotech, INC. | $16.88 | 2020 | |
| Convatec INC. | $15.88 | 2024 | |
| Sumitomo Pharma America, INC. | $14.42 | 2025 | Gemtesa |
| Coloplast Corp | $13.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.